Skip to main content
. 2021 Feb 24;66(11):3929–3937. doi: 10.1007/s10620-021-06872-z

Table 2.

Association between famotidine use and COVID-19 outcomes

Analysis Number of studies OR (95% CI) P Heterogeneity
PHeterogeneity I2 (%)
Severity, mortality and intubation 5 0.82(0. 52–1.30) 0.400 0.003 76
Mortality and intubation 3 0.63(0.35–1.16) 0.140 0.002 84
Mortality only 3 0.90(0.49–1.65) 0.730 0.003 82